Unibest 优贝德

APIs Recommended for You

Three inputs drive the ranking: the region of your target market, the indication classes you follow, and each molecule's patent-expiry window. Every card states why it was picked.

What drives these picks

Region
北美

合规与文件成本最高,但单价与订单体量最大

Indications you follow
Animal Health
Visitor region (by IP)
USip

ANDA 路线;原料端需 DMF 并在 ANDA 中引用,US GMP 与场地登记是硬条件

No direction yet? This page picks from our catalogue. To answer what a market will need next, use the demand-chain board and work down from economy, demography and diet.

Demand-chain board →

Which therapeutic areas do you follow?

Multi-select, change any time

Sign in and we remember your market and interests — you land straight on this page next time.

Animal HealthTo be assessed4 intermediates
Afoxolaner

Prevention and treatment of flea, tick and certain mite infestations in dogs and cats

Why it was picked
  • · 你关注的适应症:动物保健(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Animal HealthTo be assessed5 intermediates
Fluralaner

Long-acting eradication of fleas and ticks in dogs and cats

Why it was picked
  • · 你关注的适应症:动物保健(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Animal HealthTo be assessed3 intermediates
Lotilaner

Ectoparasite control in dogs and cats; ophthalmic use for demodex blepharitis

Why it was picked
  • · 你关注的适应症:动物保健(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Animal HealthTo be assessed2 intermediates
Sarolaner

Prevention and treatment of flea, tick and other ectoparasite infestations in dogs and cats

Why it was picked
  • · 你关注的适应症:动物保健(+35)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Cardiovascular / RenalOff-patent · 1995
Methyldopa hydrate

Treatment of hypertension, especially pregnancy-induced hypertension

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(+25)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyOff-patent · 2026 (indicative)
Ruxolitinib

Myelofibrosis and polycythemia vera; topical formulations for vitiligo and atopic dermatitis

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(+25)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Cardiovascular / RenalExpiring within 2 yrs · 2027 (indicative)
Edoxaban

Stroke prevention in non-valvular atrial fibrillation; treatment of DVT and pulmonary embolism

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 2 年内到期(+20)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
Oncology / HematologyTo be assessed3 intermediates
Apalutamide

Non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
Cardiovascular / RenalTo be assessed6 intermediates
Finerenone

Chronic kidney disease (CKD) associated with type 2 diabetes; slows renal function decline and cardiovascular events

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 待评估(+2)
  • · 已商业化可供(+10)
  • · 已收录关键中间体,可沿供应链往下采购(+15)
  • · GMP / DMF 就绪(+4)
CNS / PsychiatryOff-patent · 2020 (to verify)
Eliprodil

Exploratory indications: neuropathic pain, post-stroke neuroprotection

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(待核实)(+10)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
CNS / PsychiatryOff-patent · 2020 (to verify)
Elzasonan

Depressive and anxiety disorders

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(待核实)(+10)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)
CNS / PsychiatryOff-patent · 2020 (to verify)
Emapunil

Anxiety and other mood disorders

Why it was picked
  • · 北美需求旺盛类目(+30)
  • · 已到期(待核实)(+10)
  • · 已商业化可供(+10)
  • · GMP / DMF 就绪(+4)

Patent expiry compiled from public sources and indicative only; defer to national patent offices and the Orange Book.